January 24, 2024 7:42am

As some recent buys have pulled back while earnings season is ramping up to full force is another reason to be cautious.

A Very weak aftermarket

The Bottom Line: WHY do I keep analyzing Harvard Apparatus GN (HRGN)? <read more>

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What RMi provides is a trusted source of share pricing intelligence. Join me … in the NO spin zone!

Never leave an investor uninformed!

Remember that overnight action in a.m. futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

I make a commitment to provide need-to-know “facts in evidence” as an equity’s volatility is one tactical signal for stocks. My thesis is important in trying to distinguish the temporary from real pricing digression or progression.

I also follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

Wednesday: The pre-open Dow futures are UP +22% or (+85 points), the S&P futures are UP +0.42% or (+20 points) as the Nasdaq futures are UP +0.67% or (+117 points)

Futures are positively up on Wednesday a.m.,

European markets opened higher

Asia Pacific markets were mixed as Japan extended its losses

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Tuesday, indexes closed mixed in a quiet session, the Dow pulled back -96 points or -0.25%, the S&P progressed +14.17 points or +0.29% while the Nasdaq jumped +65.66 points or +0.43%.

Economic Data Docket: manufacturing and services data for January

 

52-week low:

  • bluebird bio (BLUE) at $1.17

 

Q1/24: 2 holidays, 8 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

I am passing on forecasting the daily indications – the aftermarket is just a sloppy nothing …  it is just mixed of some ups, fewer downs and a flat

Notice the flow … I perceive some slippage on Wednesday:

  • Tuesday closed positive with 21 incliners, 13 decliners and 1 flat
  • (1/22) Monday closed positive with 28 incliners, 7 decliners and 0 flat
  • Friday closed positive with 21 incliners, 13 decliners and 1 flat

 

The BOTTOM LINE: Tuesday was a day off for me, just too many things going-on with family.

  • The cell and gene therapy sector had shown more flickers of strength.
  • Remember, buying opportunities will appear when the market is on a short-term upswing, only for those sector equities to fall back.

Coming attractions …Q4 and FY23 reporting season and “runways” will get measured as consensus and estimates will get missed!

It's not surprising that the sector takes a step back today while hitting the pause button.

  • The small-cap Russell 2000 fell 0.4%, but held the bulk of its three-day advance and closed above the 21-day line.
  • The 10-year Treasury yield climbed five basis points to 4.14%, right up to the 50-day line.

For the next few weeks, if you're buying on weakness, you might be jumping onto a sinking ship even as … Q4 and FY23 earnings LPS (loss-per-share) are due even though some highlights were delivered to facilitate JPM presentations – there are consensus and beaten estimates to be reckoned!

 

WHY do I keep analyzing Harvard Apparatus GN (HRGN) formerly, Biostage (BSTG): I WAS there to experience the lack of investor prerogatives and saw the decay of transparency, investor manipulation and more; it takes courage, resolve and patience to stay the course of asking the questions without response!

  • Question: WHY does Chinese investor DST Capital and Beijing based D. Phone and its sub Dixintong Technology Group need - Harvard Apparatus GN (OTCQB: HRGN) an OTC listed money losing ($90.1 M since split from HBIO) company that resides in the middle of medical and scientific innovation in America?
  • Question#2: A Ponzi Scheme or just a MSS (Chinese Security Servies) “plant” – check the Beijing, China officers, directors and employees and from where the “investment/money” flows aligned with Lui Dong Hai, chairman of D. Phone, the largest smartphone retailer in China; also, the husband of Mrs. bin Zhao, who resides in Weston, Ma. of DST Capital?
  • Question#3: WHY does Chinese investor DST Capital and Beijing based D. Phone and its sub Dixintong Technology Group need a regenerative medicine/biotech public and money losing company in its investment group that resides in the middle of medical and scientific innovation in America?

Pricing for gene therapies will continue to dominate share ascensions and downfalls!

  • It's also a good idea to take some profits, especially if you didn't do so in past sessions. <IBD>

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.